IPO registrations (S-1, F-1) · Registrants
Protagonist Therapeutics, Inc
- SEC CIK
- 1377121 · filings on EDGAR ↗
- Former names
- Protagonist Therapeutics Inc (2013–2013); Protagonist Inc (2006–2006)
- Registration
- Form S-1, first filed 2016-07-11, last 2016-08-09; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2016-08-12; declared effective 2016-08-10
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 7707 GATEWAY BLVD., SUITE 140, Newark, CA 94560-1160
- EIN
- 98-0505495
- Ticker
- PTGX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Protagonist Therapeutics, Inc on the corporate pages
Offering terms
- Proposed price range
- $11.00–$13.00 per share (S-1/A filed 2016-08-01)
- Final price
- $12.00 per share, within the range (424B4 filed 2016-08-12, an initial public offering)
- Shares sold
- 7,500,000
- Gross proceeds
- $90,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol PTGX
- Lead underwriters
- Leerink Partners (3,000,000 shares); Barclays (3,000,000 shares)
- Syndicate
- BMO Capital Markets (1,500,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: PROTAGONIST THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: PROTAGONIST THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Federal award recipient: PROTAGONIST THERAPEUTICS, INC. Fuzzy (name and state)
- Form D issuer: Protagonist Therapeutics, Inc EXACT (CIK (EXACT))
- SEC filer: Protagonist Therapeutics, Inc EXACT (CIK (EXACT))
- Person page: Sarah A O'Dowd Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: S Edward Torres Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2016-07-11 | S-1 | S-1 (registration) | Protagonist Therapeutics, Inc | 0001193125-16-645574 ↗ |
| 2016-08-01 | S-1/A | S-1/A (amendment) | Protagonist Therapeutics, Inc | 0001193125-16-665762 ↗ |
| 2016-08-09 | S-1/A | S-1/A (amendment) | Protagonist Therapeutics, Inc | 0001193125-16-675649 ↗ |
| 2016-08-10 | S-1MEF | S-1MEF (added securities) | Protagonist Therapeutics, Inc | 0001193125-16-678378 ↗ |
| 2016-08-10 | EFFECT | EFFECT (declared effective) | Protagonist Therapeutics, Inc | 9999999995-16-005408 ↗ |
| 2016-08-12 | 424B4 | 424B4 (final prospectus) | Protagonist Therapeutics, Inc | 0001193125-16-679590 ↗ |
| 2017-10-05 | EFFECT | EFFECT (declared effective) | Protagonist Therapeutics, Inc | 9999999995-17-002597 ↗ |
Prospectus pages read 3
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2016-08-01 | S-1/A | registration statement | $11.00–$13.00 | 5,835,000 | - | Nasdaq PTGX | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2016-08-09 | S-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2016-08-12 | 424B4 | final prospectus | $12.00 | 7,500,000 | $90,000,000 | Nasdaq PTGX | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Canaan Partners X LLC | Director,TenPercentOwner; TenPercentOwner | 8 | 2016–2018 | ||
| CANAAN X L.P. | Director,TenPercentOwner; TenPercentOwner | 8 | 2016–2018 | ||
| Hall Steven Edward | TenPercentOwner | 2 | 2016 | ||
| HODDER WILLIAM A | Officer | Sr. VP - Corporate Development | 2 | 2016 | |
| JOHNSON & JOHNSON | TenPercentOwner | 2 | 2016 | ||
| Johnson & Johnson Innovation - JJDC, Inc. | TenPercentOwner | 2 | 2016 | ||
| KHOSLA CHAITAN PHD | Director | 10 | 2016–2020 | ||
| Lilly Ventures Fund I LLC | TenPercentOwner | 2 | 2016 | ||
| Liu David Y | Officer | Chief R&D Strategy Officer; Chief Scientific Officer | 20 | 2016–2022 | |
| LV Management Group, LLC | TenPercentOwner | 2 | 2016 | ||
| O'Neil Thomas P. | Officer | Chief Financial Officer | 5 | 2016–2018 | |
| Papanek Julie | Director | 4 | 2016–2017 | ||
| PATEL DINESH V PH D | Director,Officer; Director,Officer,TenPercentOwner | President and CEO | 67 | 2016–2026 | |
| SELICK HAROLD E | Director | 19 | 2016–2026 | ||
| Shame Richard S | Officer | Chief Medical Officer | 10 | 2016–2019 | |
| Shanafelt Armen | Director,TenPercentOwner | 5 | 2016–2018 | ||
| Torres S. Edward | TenPercentOwner | 2 | 2016 | person page Fuzzy | |
| Waddill William D. | Director | 25 | 2016–2026 | ||
| Adage Capital Advisors, L.L.C. | TenPercentOwner | 2 | 2017–2018 | ||
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TenPercentOwner | 2 | 2017–2018 | ||
| Adage Capital Partners, L.P. | TenPercentOwner | 2 | 2017–2018 | ||
| Atchinson Robert | TenPercentOwner | 2 | 2017–2018 | ||
| Gross Phillip | TenPercentOwner | 2 | 2017–2018 | ||
| Williams Lewis T | Director | 12 | 2017–2026 | ||
| Noonberg Sarah B. | Director | 10 | 2017–2023 | ||
| Giraudo Bryan | Director | 13 | 2018–2026 | ||
| Saks Samuel R | Officer | Chief Development Officer; Chief Medical Officer | 6 | 2018–2021 | |
| Gupta Suneel | Officer | Chief Development Officer; EVP Clinical Operations | 16 | 2019–2024 | |
| Murphy Niall | Officer | VP, Controller, Interim PAO | 1 | 2019 | |
| Kalkofen Donald A. | Officer | Chief Financial Officer | 6 | 2019–2022 | |
| O'Dowd Sarah A | Director | 8 | 2020–2026 | person page Fuzzy | |
| Ali Asif | Officer | Chief Financial Officer | 19 | 2022–2026 | |
| MOLINA ARTURO MD | Officer | Chief Medical Officer | 16 | 2022–2026 | |
| Swisher Daniel N JR | Director | 2 | 2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2015-07-24 | Protagonist Therapeutics, Inc | Biotechnology | $40,000,000 | $17,499,999 | 9 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | PROTAGONIST THERAPEUTICS, INC. | CA | State business registries | name and state |
| Plan sponsor | PROTAGONIST THERAPEUTICS, INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Federal award recipient | PROTAGONIST THERAPEUTICS, INC. | CA | Federal spending (USAspending) | name and state |
| Form D issuer | Protagonist Therapeutics, Inc | CA | Form D private offerings | CIK (EXACT) |
| Patent assignee | PROTAGONIST THERAPEUTICS, INC. | CA | Patents (USPTO) | name and state |
| SEC filer | Protagonist Therapeutics, Inc | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Protagonist Therapeutics, Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | PROTAGONIST THERAPEUTICS, INC. | EIN (EXACT) | ||
| Person page | Sarah A O'Dowd | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | S Edward Torres | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.